BioCytics Awarded a G-Rex Grant From ScaleReady
BioCytics Awarded a G-Rex Grant From ScaleReady
"The grant award will allow us to accelerate the development of our IND-bound immune fraction BCyIF1 against solid tumors," states Dr. HUNTERSVILLE, N.C., Dec. 3, 2024 /PRNewswire/ -- BioCytics is pleased to announce it has been awarded a $100,000 G-Rex grant from ScaleReady. This grant was given in support of BioCytics' efforts to develop and optimize a cGMP G-Rex-based manufacturing process to produce immune cell fractions that are a major component of BioCytics' platform therapy to treat tumors. This therapy involves isolating, expanding, and activating specific fractions of a patient's own immune cells to fight their cancer.
BioCytics很高興宣佈獲得了來自ScaleReady的10萬美元G-Rex補助金。這筆補助金是爲了支持BioCytics制定和優化cGMP G-Rex製造過程，生產免疫細胞分離物，這是BioCytics平台治療腫瘤的重要組成部分。這種治療涉及隔離、擴增和激活患者自身免疫細胞的特定分離物，以對抗他們的癌症。
The G-Rex Grant is part of ScaleReady's $20 million grant program aimed at advancing Cell and Gene Therapy (CGT) development and manufacturing. The G-Rex Grant Program offers recipients significant support allowing for expeditious optimization of cell manufacturing processes.
G-Rex補助是ScaleReady的2000萬美元補助計劃的一部分，旨在推進細胞和基因療法（CGT）的開發和製造。G-Rex補助計劃爲受贈者提供重要支持，可以加速優化細胞製造流程。
BioCytics, Inc. has received a $100,00 G-rex grant to help develop their cell-based approach to solid tumor treatment.
BioCytics公司已獲得10萬美元的G-rex補助金，以幫助發展他們基於細胞的實體腫瘤治療方法。
"The grant award will allow us to accelerate the development of our IND-bound immune fraction BCyIF1 against solid tumors," states Dr. Renaud Warin, BioCytics Chief Scientific Officer. "Through this award, we will obtain, at no cost, access to ScaleReady's range of products and low cost access to the products and expertise of their collaborating companies. The collective cell therapy knowledge base that is at our disposal is exceptional."
「這項補助將幫助我們加快發展針對實體腫瘤的IND綁定免疫分離物BCyIF1，」BioCytics首席科學官雷諾•瓦蘭博士表示。「通過這個獎項，我們將免費獲得ScaleReady的產品系列和低成本獲得其合作公司的產品和專業知識。我們可以利用的集體細胞治療知識庫是非常特殊的。」
"This is yet another example of how ScaleReady is willing and able to go beyond the traditional business model to do all it can to advance the field of cell and gene therapy," said Josh Ludwig, Commercial Director of ScaleReady. "In the cause of advancing BioCytics' mission, we are eager to help them bring novel, affordable, re-invigorated immune cell cancer therapies directly to the patient through Point-of-Care manufacturing."
「這是ScaleReady願意並有能力超越傳統業務模式，盡一切可能推動細胞和基因治療領域的進展的又一個例子，」ScaleReady商務總監喬什•路德維格表示。「爲了推進BioCytics的使命，我們渴望幫助他們通過POC製造將新穎、負擔得起、重振免疫細胞癌症療法直接帶給患者。」
About BioCytics, Inc.
BioCytics, founded in 2005, is a privately held health technology company co-located in Huntersville, North Carolina with Carolina BioOncology Institute, a cancer treatment and clinical trial facility. BioCytics is using Autologous Adaptive Cell Therapy (AACT) to develop an immuno-oncology platform for treating solid tumors with the patient's own immune cells. AACT is a revolutionary point-of-care cell manufacturing process designed to generate nongenetically modified effector cell fractions for all stages of all solid tumors. For more information, please visit Biocytics.com or find us on LinkedIn.
關於BioCytics公司
BioCytics成立於2005年，是一家位於北卡羅來納州亨特斯維爾，與卡羅萊納生物腫瘤學院共處的私人健康技術公司。BioCytics正在使用自體適應性細胞療法（AACT）開發免疫腫瘤平台，用患者自身的免疫細胞治療實體腫瘤。AACT是一種革命性的現場細胞製造過程，旨在爲所有實體腫瘤的所有階段生成非基因編輯的效應細胞分離物。欲了解更多信息，請訪問Biocytics.com或在LinkedIn上查找我們。
About ScaleReady
ScaleReady provides the field of cell and gene-modified cell therapy (CGT) with a G-Rex centric manufacturing platform that enables the world's most practical, flexible, scalable, and affordable CGT drug product development and manufacturing. The G-Rex manufacturing platform is currently used by a rapidly growing list of over 800 organizations and is producing drug products for approximately 50% of CGT clinical trials as well as 5 commercially approved CGT drugs. CGT entities relying on the breadth and scope of ScaleReady's expertise can expect to save years of time and millions of dollars on the path to CGT commercialization. For more information about the ScaleReady G-Rex Grant Program, please contact [email protected].
關於 ScaleReady
ScaleReady爲細胞和基因修飾細胞治療（CGT）領域提供了一個以G-Rex爲中心的製造平台，這讓全球最實用、靈活、可擴展和負擔得起的CGt藥物開發和製造成爲可能。目前，G-Rex製造平台已被800多個組織廣泛使用，爲約50%的CGt臨床試驗以及5種商業獲批的CGt藥物生產藥物。依賴於ScaleReady專業知識的CGt實體可以預期在通向CGt商業化道路上節省數年的時間和數百萬美元。有關ScaleReady G-Rex授予計劃的更多信息，請聯繫[email protected]。
About Wilson Wolf Manufacturing Corporation
Wilson Wolf () is dedicated to simplifying cell and gene-modified cell (CGT) therapy research, process development, and manufacturing. This is being accomplished through its scalable G-Rex technology, which is used throughout the world in CGT applications ranging from basic research to commercial drug production. Wilson Wolf's mission is to create hope for cancer patients, one G-Rex device at a time.
關於Wilson Wolf製造公司
Wilson Wolf（）致力於簡化細胞和基因修飾細胞（CGT）療法研究、工藝開發和製造。通過其可擴展的G-Rex技術，這一目標已在全球範圍內在從基礎研究到商業藥物生產的各種CGt應用中實現。Wilson Wolf的使命是逐個G-Rex設備爲癌症患者創造希望。
About Bio-Techne Corporation
Bio-Techne Corporation is a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities. Bio-Techne, in partnership with Wilson Wolf, is creating products such as media and cytokines that are specifically tailored to G-Rex Bioreactors, including right-sized reagent quantities in containers that are tailored to high throughput closed-system manufacturing. For more information on Bio-Techne and its brands, please visit or follow the Company on social media at: Facebook, LinkedIn, Twitter or YouTube.
關於Bio-Techne公司
Bio-Techne Corporation是一家全球生命科學公司，爲研究和臨床診斷社區提供創新工具和生物活性試劑。Bio-Techne與Wilson Wolf合作，創建了專門針對G-Rex生物反應器的介質和細胞因子等產品，其中包括量身定製的適用於高送轉封閉式系統製造的合適試劑數量以及容器。有關Bio-Techne及其品牌的更多信息，請訪問 或在社交媒體上關注該公司的Facebook、LinkedIn、Twitter或YouTube。
SOURCE BioCytics Inc.
源BioCytics Inc。
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
想要您公司的新聞在PRNEWSWIRE.COM上特色呈現嗎？
譯文內容由第三人軟體翻譯。